产品封面图
文献支持

U-2932细胞系

收藏
  • ¥2450
  • BHcell(博辉生物)
  • H-C2031
  • 2026年01月14日
    avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    U-2932细胞U-2932细胞系U-2932人弥漫大B淋巴瘤细胞

    Cell line name U-2932

    Synonyms U2932

    Accession CVCL_1896

    Resource Identification Initiative To cite this cell line use: U-2932 (RRID:CVCL_1896)

    Comments Part of: LL-100 blood cancer cell line panel.

    Part of: MD Anderson Cell Lines Project.

    Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).

    Doubling time: 48 hours (PubMed=12533045); ~50 hours (DSMZ=ACC-633).

    Omics: Array-based CGH.

    Omics: Cell surface proteome.

    Omics: Deep exome analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Donor information: Originally the patient was suffering from Hodgkin lymphoma.

    Derived from site: In situ; Ascites; UBERON=UBERON_0007795.

    HLA typing Source: PubMed=26589293

    Class I

    HLA-A A*01:01,03:01

    HLA-B B*08:01,15:01

    HLA-C C*03:04,07:01

     

    Source: DSMZCellDive=ACC-633

    Class I

    HLA-A A*01:01:01,03:01:01

    HLA-B B*08:01:01,15:01:01

    HLA-C C*03:04:01,07:01:01

    Class II

    HLA-DP DPA1*01:03:01,01:03:01

    DPB1*04:01:01,03:01:01

    HLA-DQ DQA1*03:01:01,05:01:01

    DQB1*02:01:01,03:02:01

    HLA-DR DRA*01:01:01,01:02:02

    DRB1*03:01:01,04:01:01

    Disease Diffuse large B-cell lymphoma activated B-cell type (NCIt: C36081)

    Diffuse large B-cell lymphoma (ORDO: Orphanet_544)

    PubMed=12533045; DOI=10.1080/1042819021000032917

    Amini R.-M., Berglund M., Rosenquist R., von Heideman A., Lagercrantz S., Thunberg U., Bergh J., Sundstrom C., Glimelius B., Enblad G.

    A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma.

    Leuk. Lymphoma 43:2179-2189(2002)

     

    PubMed=20054396; DOI=10.1038/nature08638; PMCID=PMC2845535

    Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. 3rd, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pierce S.K., Staudt L.M.

    Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

    Nature 463:88-92(2010)

     

    PubMed=23257783; DOI=10.1038/leu.2012.367

    Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.

    MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.

    Leukemia 27:1381-1390(2013)

     

    PubMed=23292937; DOI=10.1073/pnas.1205299110; PMCID=PMC3557051

    Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W.W.-L., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K.N., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.

    Genetic heterogeneity of diffuse large B-cell lymphoma.

    Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)

     

    PubMed=23295736; DOI=10.1038/leu.2012.358

    Quentmeier H., Amini R.-M., Berglund M., Dirks W.G., Ehrentraut S., Geffers R., MacLeod R.A.F., Nagel S., Romani J., Scherr M., Zaborski M., Drexler H.G.

    U-2932: two clones in one cell line, a tool for the study of clonal evolution.

    Leukemia 27:1155-1164(2013)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=25894527; DOI=10.1371/journal.pone.0121314; PMCID=PMC4404347

    Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.

    A mass spectrometric-derived cell surface protein atlas.

    PLoS ONE 10:E0121314-E0121314(2015)

     

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

    Genome Med. 7:118.1-118.7(2015)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由博辉生物科技(广州)有限公司提供; *发表【英文论文】请标注:From Bohui Biological Technology (Guangzhou) Co., Ltd.

    相关实验
    • PNAS:RAS 抑制剂又添一员,新型蛋白模拟物或为癌症治疗

      12X 突变体 H-Ras 与 CHDSos-5 的肽滴定实验表明,蛋白模拟物在类似的低微摩尔亲和力范围内结合所有 Ras 蛋白。随后研究团队评估了 Sos 蛋白模拟物抑制细胞中 Ras 信号转导的潜力。MTT 细胞活性实验发现,与野生型细胞系相比,CHDSos-5 对含有致癌 Ras 突变的细胞系表现出浓度依赖性毒性,并且细胞活性与不同细胞系间固有的巨胞饮摄取水平呈负相关。这些结果表明,利用上调的巨胞饮作用为突变癌细胞提供治疗提供了潜在优势。图片来源:PNAS化学蛋白质组学分析揭示了 CHDSos-5

    • RNAi技术专题之:体外转录合成双链RNA

      的结合和解链),无反向重复序列(有利于减小siRNA的有效作用浓度,提高siRNA干扰效率),正义链碱基的偏爱性A19(正义链中第19位碱基为A,如下表示类同);A3;U10;无G/C(正义链中第19位碱基不为G或C);无G13。依此规则,Reynolds等设计的30条siRNA中有29条是有效的。Kumiko等亦认为siRNA反义链5’端为A/U(即有义链U/A)19和最后7个碱基中有5个A/U,会有助于RNAi的高效发挥,且正义链G/C1和序列中无连续9nt以上的GC重复片段与基因沉默效率呈显著

    • 【求助】ly294002处理细胞添加浓度

      1/2 特异性抑制剂U0126预处理食管癌细胞系,处理的浓度都达到了50uM了,但是用western-blotting检测p-ERK1/2的表达水平,一点都没有减少的意思,反而好像增加了(与低浓度相比),当时很郁闷啊!后来分析其原因,可能是高浓度的U0126中含有的DMSO的体积较高,高浓度的DMSO会激活ERK1/2通路的表达。 shutaozheng_824 其实,我也出现过类似的情况啊!当时我在用MAPK/ERK1/2 特异性抑制剂U0126预处理食管癌细胞系

    图标技术资料

    资料下载:

    U-2932(BH-C2031).docx 附 (下载 0 次)

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥900
    安元生物科技(南京)有限公司
    2025年07月16日询价
    ¥2000
    上海盖宁生物科技有限公司
    2026年03月20日询价
    ¥550
    深圳市康初源有限公司
    2026年01月24日询价
    ¥2000
    上海匹拓生物科技有限公司
    2026年03月30日询价
    ¥1320
    博辉生物科技(广州)有限公司
    2026年01月14日询价
    文献支持
    U-2932细胞系
    ¥2450